Kronos Bio Incorporated is a biopharma developing novel cancer therapeutics. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. The company's lead product candidate is entospletinib (ENTO), an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. It is also developing KB-0742, a bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio was incorporated in 2017 and is headquartered in San Mateo, CA.
What is Kronos Bio's quote symbol?
What is the 52 week high and low for Kronos Bio (NASDAQ: KRON)?
How much is Kronos Bio stock worth today?
How much is Kronos Bio's stock price per share?
What is Kronos Bio's Market Cap?